Angelman Syndrome Clinical Trial
— ELARAOfficial title:
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
Verified date | January 2022 |
Source | Ovid Therapeutics Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This open-label study (OV101-18-002) will evaluate the long-term (52 weeks) safety of OV101 in subjects with AS and provide additional OV101 treatment to those subjects who completed Study OV101-15-001 (NCT02996305). Subjects with AS who completed the pharmacokinetic Study OV101-16-001 (NCT03109756) will also be permitted to participate, provided they meet all entry criteria.
Status | Terminated |
Enrollment | 125 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 49 Years |
Eligibility | Inclusion Criteria: Each subject must meet all the following criteria to be enrolled in this study: 1. Has completed the OV101-15-001 or OV101-16-001 study up to the EOS. 2. Is male or female and 13 to 49 years old (inclusive) at the time of inclusion in the OV101-15-001 or OV101-16-001 study. 3. Has a previous diagnosis of AS with molecular confirmation from the OV101-15-001 or OV101-16-001 study. 4. Has an LAR/caregiver capable of providing informed consent and able to attend all scheduled study visits, oversee the administration of study drug, and provide feedback regarding the subject's symptoms and performance as described in the protocol. 5. Provides assent to the protocol (to the extent possible and in accordance with local institutional review board (IRB) and regulatory requirements) and has an LAR/caregiver who will provide written informed consent. Subjects providing assent must do so at the same visit as LAR/caregiver written informed consent is provided. 6. Can swallow study drug capsules or ingest the contents of study drug capsules after sprinkling the capsule contents onto 1 spoon of applesauce or low-fat yogurt. 7. Is currently receiving a stable dose of concomitant medications such as anti-epileptic medication, gabapentin, clonidine, trazadone, melatonin, and special diets for at least 4 weeks prior to Baseline. 8. Agrees to remain sexually abstinent from the first day of screening until 30 days after the last dose of study treatment. 9. Has LAR/caregiver(s) who agree not to post any of the subject's personal medical data or information related to the study on any website or social media site (eg, Facebook, Instagram, Twitter) until notified that the study is completed. Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. Discontinued from the OV101-15-001 or OV101-16-001 study due to safety reasons causally related to OV101. 2. Has a concomitant disease (eg, gastrointestinal, renal, hepatic, endocrine, respiratory, or cardiovascular system disease) or condition or any clinically significant finding at Screening that could interfere with the conduct of the study or that would pose an unacceptable risk to the subject in this study. 3. Has poorly controlled seizures defined as > 3 seizures lasting < 3 minutes per week or > 1 seizure episode lasting more than 3 minutes per week or as per medical monitor judgment. 4. Has clinically significant clinical laboratory abnormalities or vital signs at the time of screening (eg, alanine aminotransferase or aspartate aminotransferase > 2.5 × upper limit of normal; total bilirubin or creatinine > 1.5 × upper limit of normal). Retesting of clinical laboratory parameters may be allowed after consultation with the medical monitor or designee. 5. Current use of benzodiazepines, zolpidem, zaleplon, zopiclone, eszopiclone, barbiturates, or ramelteon for sleep within the 4 weeks prior to Day 1. Benzodiazepines administered for situational anxiety related to occasional procedures or events are permitted. 6. Has a history of suicidal behavior or is considered by the investigator to be at increased risk of suicide. 7. Has any condition or circumstance that, in the opinion of the investigator, makes the subject unsuitable for enrollment. 8. Has enrolled in any clinical trial or used any investigational agent or device, or has participated in any investigational procedure, within the 30 days before screening or does so concurrently with this study. 9. Is a family member of the investigator or of study site staff. |
Country | Name | City | State |
---|---|---|---|
Israel | Ovid Therapeutics Investigative Site | Ramat Gan | |
United States | Ovid Therapeutics Investigative Site | Atlanta | Georgia |
United States | Ovid Therapeutics Investigative Site | Boston | Massachusetts |
United States | Ovid Therapeutics Investigative Site | Chicago | Illinois |
United States | Ovid Therapeutics Investigative Site | Cincinnati | Ohio |
United States | Ovid Therapeutics Investigative Site | Lexington | Massachusetts |
United States | Ovid Therapeutics Investigative Site | Media | Pennsylvania |
United States | Ovid Therapeutics Investigative Site | Nashville | Tennessee |
United States | Ovid Therapeutics Investigative Site | Phoenix | Arizona |
United States | Ovid Therapeutics Investigative Site | San Diego | California |
United States | Ovid Therapeutics Investigative Site | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
Ovid Therapeutics Inc. |
United States, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events in active treatment group | Safety assessments related to the primary study objective of evaluating safety and tolerability of OV101 will include frequency, severity, and causality of AEs (including SAEs and AEs leading to study discontinuation), clinical assessment of suicidality, vital sign measurements, physical examinations, and EEG evaluations. | Change from baseline to Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05293184 -
The Global Angelman Syndrome Registry
|
||
Completed |
NCT00004351 -
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
|
N/A | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT06229769 -
Natural History Study for Patients With Angelman Syndrome
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT03235037 -
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
|
N/A | |
Recruiting |
NCT05100810 -
Angelman Syndrome Natural History Study-FAST UK
|
||
Completed |
NCT03644693 -
Nutritional Formulation for Angelman Syndrome
|
N/A | |
Completed |
NCT03358823 -
Study on the Brain Network of Angelman Syndrome
|
||
Recruiting |
NCT06337383 -
Study of the Prevalence of Autistic Traits in Angelman Syndrome
|
||
Recruiting |
NCT05945576 -
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
|
||
Completed |
NCT02670694 -
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
|
N/A | |
Recruiting |
NCT04768803 -
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
|
||
Recruiting |
NCT05630066 -
Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
|
Phase 2 | |
Completed |
NCT00348933 -
Dietary Supplements for the Treatment of Angelman Syndrome
|
N/A | |
Recruiting |
NCT05011851 -
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
|
Phase 2 | |
Completed |
NCT02996305 -
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
|
Phase 2 | |
Completed |
NCT02056665 -
Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome
|
Phase 2 | |
Completed |
NCT01281475 -
A Trial of Levodopa in Angelman Syndrome
|
Phase 2/Phase 3 |